The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Genomic Classification and Prognosis in Acute Myeloid Leukemia
Open accessAbstract
BACKGROUND: Recent studies have provided a detailed census of genes that are mutated in acute myeloid leukemia (AML). Our next challenge is to understand how this genetic diversity defines the pathophysiology of AML and informs clinical practice. METHODS: We enrolled a total of 1540 patients in three prospective trials of intensive therapy. Combining driver mutations in 111 cancer genes with cytogenetic and clinical data, we defined AML genomic subgroups and their relevance to clinical outcomes. RESULTS: We identified 5234 driver mutations across 76 genes or genomic regions, with 2 or more drivers identified in 86% of the patients. Patterns of co-mutation compartmentalized the cohort into 11 classes, each with distinct diagnostic features and clinical outcomes. In addition to currently defined AML subgroups, three heterogeneous genomic categories emerged: AML with mutations in genes encoding chromatin, RNA-splicing regulators, or both (in 18% of patients); AML with TP53 mutations, chromosomal aneuploidies, or both (in 13%); and, provisionally, AML with IDH2(R172) mutations (in 1%). Patients with chromatin-spliceosome and TP53-aneuploidy AML had poor outcomes, with the various class-defining mutations contributing independently and additively to the outcome. In addition to class-defining lesions, other co-occurring driver mutations also had a substantial effect on overall survival. The prognostic effects of individual mutations were often significantly altered by the presence or absence of other driver mutations. Such gene-gene interactions were especially pronounced for NPM1-mutated AML, in which patterns of co-mutation identified groups with a favorable or adverse prognosis. These predictions require validation in prospective clinical trials. CONCLUSIONS: The driver landscape in AML reveals distinct molecular subgroups that reflect discrete paths in the evolution of AML, informing disease classification and prognostic stratification. (Funded by the Wellcome Trust and others; ClinicalTrials.gov number, NCT00146120.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We identified 391 out of the 622 curated COSMIC cancer-related and AML-related genes located inside the altered TADs in at least one sample, and more than 100 are recurrent across multiple samples (Extended Data Fig. 3b)4,24,25.”
From Subtype-specific 3D genome alteration in acute myeloid leukaemia (2022) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Splicing factor mutations are common in AMl and other blood malignancies and are often mutually exclusive (Haferlach et al. 2014;Papaemmanuil et al. 2016), indicating that cancers harboring such mutations may rely on an intact splicing machinery for survival (lee et al. 2018).”
From From serendipity to strategy: molecular glue degraders in cancer therapeutics (2025) · cites this paper as Papaemmanuil et al. 2016
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Leukemia is frequently driven by mutations in epigenetic modifiers or signaling master regulators58 that lead to gross alterations of the epigenetic landscape59 and an epigenetic environment widely permissive of activation.”
From Design principles of cell-state-specific enhancers in hematopoiesis (2025) · cites this paper as [58]
In the citing paper
“Particularly in acute myeloid leukemia (AML), a prominent component of the disease is recurrent mutations in spliceosome machinery and genome-wide aberrant splicing events (14)(15)(16)(17).”
From Discovery of a Novel CIP2A Variant (NOCIVA) with Clinical Relevance in Predicting TKI Resistance in Myeloid Leukemias (2021) · cites this paper as [16]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078
Age-related clonal hematopoiesis associated with adverse outcomes
Jaiswal, S., Fontanillas, P., Flannick, J., Manning, A., Grauman, P. V., Mar, B. G., Lindsley, R. C., Mermel, C. H., Burtt, N., Chavez, A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408617 · Cited by 4,841
Vardiman, J. W., Thiele, J., Arber, D. A., Brunning, R. D., Borowitz, M. J., Porwit‐MacDonald, A., Harris, N. L., Beau, M. M. L., Hellström‐Lindberg, E., Tefferi, A., et al. (2009) · Blood · doi:10.1182/blood-2009-03-209262 · Cited by 4,532
Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence
Genovese, G., Kähler, A. K., Handsaker, R. E., Lindberg, J., Rose, S. A., Bakhoum, S. F., Chambert, K., Mick, E., Neale, B. M., Fromer, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409405 · Cited by 3,531
Döhner, H., Weisdorf, D. J., & Bloomfield, C. D. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1406184 · Cited by 3,468
Self-citationDöhner, H., Estey, E. H., Amadori, S., Appelbaum, F. R., Büchner, T., Burnett, A. K., Dombret, H., Fenaux, P., Grimwade, D. J., Larson, R. A., et al. (2009) · Blood · doi:10.1182/blood-2009-07-235358 · Cited by 3,438
Self-citationGrimwade, D. J., Walker, H., Oliver, F., Wheatley, K., Harrison, C. J., Harrison, G., Rees, J., Hann, I. M., Stevens, R., Burnett, A. K., et al. (1998) · Blood · doi:10.1182/blood.v92.7.2322 · Cited by 2,649
Absolute quantification of somatic DNA alterations in human cancer
Carter, S. L., Cibulskis, K., Helman, E., McKenna, A., Shen, H., Zack, T. I., Laird, P. W., Onofrio, R. C., Winckler, W., Weir, B. A., et al. (2012) · Nature Biotechnology · doi:10.1038/nbt.2203 · Cited by 2,031
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
Patel, J. P., Gönen, M., Figueroa, M. E., Fernandez, H. F., Sun, Z., Racevskis, J., Vlierberghe, P. V., Dolgalev, I., Thomas, S., Aminova, O., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112304 · Cited by 1,990
Cited by
Sorted by citations
Items 201–300 of 1,007
Loberg, M. A., Bell, R. K., Goodwin, L. O., Eudy, E., Miles, L. A., SanMiguel, J. M., Young, K. A., Bergstrom, D. E., Levine, R. L., Schneider, R. K., et al. (2019) · Leukemia · doi:10.1038/s41375-018-0368-6 · Cited by 134
Novel therapy in Acute myeloid leukemia (AML): moving toward targeted approaches
Winer, E. S., & Stone, R. M. (2019) · Therapeutic Advances in Hematology · doi:10.1177/2040620719860645 · Cited by 133
Wang, F., Morita, K., Dinardo, C. D., Furudate, K., Tanaka, T. N., Yan, Y., Patel, K. P., MacBeth, K. J., Wu, B., Liu, G., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22874-x · Cited by 137
Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML
Wei, A. H., & Tiong, I. S. (2017) · Blood · doi:10.1182/blood-2017-08-784066 · Cited by 129
Advances in targeted therapy for acute myeloid leukaemia
Käyser, S., & Levis, M. J. (2017) · British Journal of Haematology · doi:10.1111/bjh.15032 · Cited by 127
Abarrategi, A., Mian, S. A., Passaro, D., Rouault‐Pierre, K., Grey, W., & Bonnet, D. A. (2018) · The Journal of Experimental Medicine · doi:10.1084/jem.20172139 · Cited by 130
Hackl, H., Astanina, K., & Wieser, R. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0416-0 · Cited by 130
Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation
Cocciardi, S., Dolnik, A., Kapp‐Schwoerer, S., Rücker, F. G., Lux, S., Blätte, T. J., Skambraks, S., Krönke, J., Heidel, F. H., Schnoeder, T. M., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09745-2 · Cited by 128
Self-citationClonal evolution of acute myeloid leukemia from diagnosis to relapse
Vosberg, S., & Greif, P. A. (2019) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22806 · Cited by 135
de Botton, S., Montesinos, P., Schuh, A. C., Papayannidis, C., Vyas, P., Wei, A. H., Ommen, H. B., Семочкин, С. В., Kim, H., Larson, R. A., et al. (2022) · Blood · doi:10.1182/blood.2021014901 · Cited by 124
Self-citationPrassek, V. V., Rothenberg‐Thurley, M., Sauerland, M. C., Herold, T., Janke, H., Ksienzyk, B., Konstandin, N. P., Görlich, D., Krug, U. O., Faldum, A., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.191536 · Cited by 125
Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML
Basheer, F., Giotopoulos, G., Meduri, E., Yun, H., Mazan, M. M., Sasca, D., Gallipoli, P., Marando, L., Gozdecka, M., Asby, R., et al. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20181276 · Cited by 130
Self-citationThe Role of IDH Mutations in Acute Myeloid Leukemia
Bravo, G. M., & Dinardo, C. D. (2018) · Future Oncology · doi:10.2217/fon-2017-0523 · Cited by 128
Proteomic and phosphoproteomic landscapes of acute myeloid leukemia
Kramer, M. H., Zhang, Q., Sprung, R. W., Day, R. B., Erdmann-Gilmore, P., Li, Y., Xu, Z., Helton, N., George, D. R., Mi, Y., et al. (2022) · Blood · doi:10.1182/blood.2022016033 · Cited by 124
Acute myeloid leukemia: 2021 update on risk‐stratification and management
Estey, E. H. (2020) · American Journal of Hematology · doi:10.1002/ajh.25975 · Cited by 122
Ehx, G., Larouche, J., Durette, C., Laverdure, J., Hesnard, L., Vincent, K., Hardy, M., Thériault, C., Rulleau, C., Lanoix, J., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.03.001 · Cited by 129
Kadia, T. M., Reville, P. K., Wang, X., Rausch, C. R., Borthakur, G. M., Pemmaraju, N., Daver, N. G., Dinardo, C. D., Sasaki, K., Issa, G. C., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02823 · Cited by 122
A new genomic framework to categorize pediatric acute myeloid leukemia
Umeda, M., Ma, J., Westover, T., Ni, Y., Song, G., Maciaszek, J. L., Rusch, M., Rahbarinia, D., Foy, S. G., Huang, B. J., et al. (2024) · Nature Genetics · doi:10.1038/s41588-023-01640-3 · Cited by 126
PD ‐1/ PD ‐L1 inhibitors in haematological malignancies: update 2017
Jelı́nek, T., Mihályová, J., Kaščák, M., Ďuraš, J., & Hájek, R. (2017) · Immunology · doi:10.1111/imm.12788 · Cited by 122
Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy
Liu, B., Song, Y., & Liu, D. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0541-9 · Cited by 122
Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia
Short, N. J., Kantarjian, H. M., Ravandi, F., & Daver, N. G. (2019) · Therapeutic Advances in Hematology · doi:10.1177/2040620719827310 · Cited by 122
Zhou, Y., Huang, G., Cai, X., Liu, Y., Qian, B., & Li, D. (2024) · Biomarker Research · doi:10.1186/s40364-024-00649-y · Cited by 121
Loke, J. C. T., Malladi, R. K., Moss, P. A. H., & Craddock, C. (2019) · British Journal of Haematology · doi:10.1111/bjh.16355 · Cited by 122
Bone marrow evaluation for diagnosis and monitoring of acute myeloid leukemia
Percival, M. M., Lai, C., Estey, E. H., & Hourigan, C. S. (2017) · Blood Reviews · doi:10.1016/j.blre.2017.01.003 · Cited by 122
Kapp‐Schwoerer, S., Weber, D., Corbacioglu, A., Gaidzik, V. I., Paschka, P., Krönke, J., Theis, F., Rücker, F. G., Teleanu, M., Panina, E., et al. (2020) · Blood · doi:10.1182/blood.2020005998 · Cited by 119
Self-citationGenomic Classification and Prognosis in Acute Myeloid Leukemia
Moss, P. A. H. (2016) · The Hematologist · doi:10.1182/hem.v13.5.6435 · Cited by 118
Molecular pathogenesis of the myeloproliferative neoplasms
Greenfield, G., McMullin, M. F., & Mills, K. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01116-z · Cited by 128
Warnat-Herresthal, S., Perrakis, K., Taschler, B., Becker, M., Baßler, K., Beyer, M., Günther, P., Schulte-Schrepping, J., Seep, L., Klee, K., et al. (2020) · iScience · doi:10.1016/j.isci.2019.100780 · Cited by 117
Cusan, M., Cai, S. F., Mohammad, H. P., Krivtsov, A. V., Chramiec, A. G., Loizou, E., Witkin, M. D., Smitheman, K. N., Tenen, D. G., Ye, M., et al. (2018) · Blood · doi:10.1182/blood-2017-09-807024 · Cited by 120
Emerging themes in cohesin cancer biology
Waldman, T. A. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-0270-1 · Cited by 117
Oncogenic FLT3-ITD supports autophagy via ATF4 in acute myeloid leukemia
Heydt, Q., Larrue, C., Saland, E., Bertoli, S., Sarry, J., Besson, A., Manenti, S., Joffre, C., & Mas, V. M. (2017) · Oncogene · doi:10.1038/onc.2017.376 · Cited by 125
The role of TP53 in acute myeloid leukemia: Challenges and opportunities
Barbosa, K., Li, S., Adams, P. D., & Deshpande, A. J. (2019) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22796 · Cited by 118
Rausch, C. R., Rothenberg‐Thurley, M., Dufour, A. M., Schneider, S. E., Gittinger, H., Sauerland, C., Görlich, D., Krug, U. O., Berdel, W. E., Wormann, B. J., et al. (2023) · Leukemia · doi:10.1038/s41375-023-01884-2 · Cited by 115
Wong, J. C. Y., Bryant, V. L., Westover, T., Ma, J., Walsh, M., Schwartz, J. R., Alzamora, M. D. P., Mullighan, C. G., Loh, M. L., Ribeiro, R. C., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.121086 · Cited by 114
Vasu, S., Kohlschmidt, J., Mrózek, K., Eisfeld, A., Nicolet, D., Sterling, L. J., Becker, H., Metzeler, K. H., Papaioannou, D., Powell, B. L., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2017015222 · Cited by 113
Bravo, G. M., Kanagal‐Shamanna, R., Sasaki, K., Patel, K. P., Gañán‐Gómez, I., Jabbour, E. J., Kadia, T. M., Ravandi, F., Dinardo, C. D., Borthakur, G., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018026989 · Cited by 113
Rautenberg, C., Germing, U., Haas, R. R., Kobbe, G., & Schroeder, T. A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20010228 · Cited by 113
Bezerra, M. F., Lima, A. S., Piqué‐Borràs, M., Silveira, D. R., Coelho-Silva, J. L., Pereira‐Martins, D. A., Weinhäuser, I., Franca-Neto, P. L., Quek, L. S., Corby, A., et al. (2020) · Blood · doi:10.1182/blood.2019003339 · Cited by 117
Tashakori, M., Kadia, T., Loghavi, S., Daver, N., Kanagal-Shamanna, R., Pierce, S., Sui, D., Wei, P., Khodakarami, F., Tang, Z., et al. (2022) · Blood · doi:10.1182/blood.2021013983 · Cited by 111
Acute Myeloid Leukemia: The Good, the Bad, and the Ugly
Kuykendall, A. T., Duployez, N., Boissel, N., Lancet, J. E., & Welch, J. S. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_199519 · Cited by 115
Chromothripsis in acute myeloid leukemia: biological features and impact on survival
Fontana, M. C., Marconi, G., Feenstra, J. D. M., Fonzi, E., Papayannidis, C., di Rorà, A. G. L., Padella, A., Solli, V., Franchini, E., Ottaviani, E., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0035-y · Cited by 110
Kim, T., Moon, J. H., Ahn, J., Kim, Y., Lee, S.-S., Ahn, S., Jung, S., Yang, D., Lee, J., Choi, S. H., et al. (2018) · Blood · doi:10.1182/blood-2018-04-848028 · Cited by 110
Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era?
Liu, Y., Bewersdorf, J. P., Stahl, M. F., & Zeidan, A. M. (2018) · Blood Reviews · doi:10.1016/j.blre.2018.12.001 · Cited by 112
Isocitrate dehydrogenase inhibitors in acute myeloid leukemia
Liu, X., & Gong, Y. (2019) · Biomarker Research · doi:10.1186/s40364-019-0173-z · Cited by 111
Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia: Who, When, and How?
Loke, J. C. T., Buka, R. J., & Craddock, C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.659595 · Cited by 119
Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements
Issa, G. C., Zarka, J. G., Sasaki, K., Qiao, W., Pak, D., Ning, J., Short, N. J., Haddad, F., Tang, Z., Patel, K. P., et al. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00557-6 · Cited by 113
CHIP Happens: Clonal Hematopoiesis of Indeterminate Potential and Its Relationship to Solid Tumors
Reed, S. C., Croessmann, S., & Park, B. H. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2598 · Cited by 112
Xu, Q., Li, Y., Lv, N., Jing, Y., Xu, Y., Li, Y., Li, W., Yao, Z., Chen, X., Huang, S., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2628 · Cited by 111
Li, Y., Zhang, M., Sheng, M., Zhang, P., Chen, Z., Xing, W., Bai, J., Cheng, T., Yang, F., & Zhou, Y. (2018) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-018-2631-7 · Cited by 112
Edwards, D. K., V, Watanabe‐Smith, K., Rofelty, A., Damnernsawad, A., Laderas, T., Lamble, A. J., Lind, E. F., Kaempf, A. J., Mori, M., Rosenberg, M. W., et al. (2018) · Blood · doi:10.1182/blood-2018-03-838946 · Cited by 110
Konopleva, M. Y., Thirman, M. J., Pratz, K. W., Garcia, J. S., Récher, C., Pullarkat, V. A., Kantarjian, H. M., Dinardo, C. D., Dail, M., Duan, Y., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3405 · Cited by 107
Wass, M., Göllner, S., Besenbeck, B., Schlenk, R. F., Mundmann, P., Göthert, J. R., Noppeney, R., Schliemann, C., Mikesch, J., Lenz, G., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0892-z · Cited by 106
Self-citationPatkar, N. V., Kakirde, C., Shaikh, A. F., Salve, R., Bhanshe, P., Chatterjee, G., Rajpal, S., Joshi, S., Chaudhary, S., Kodgule, R., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01131-6 · Cited by 106
Peptidomimetic blockade of MYB in acute myeloid leukemia
Ramaswamy, K., Forbes, L., Minuesa, G., Gindin, T. S., Brown, F. C., Kharas, M. G., Krivtsov, A. V., Armstrong, S. A., Still, E., de Stanchina, E., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02618-6 · Cited by 105
Khurana, A., & Shafer, D. A. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s172315 · Cited by 111
Cellular origins and genetic landscape of cutaneous gamma delta T cell lymphomas
Daniels, J., Doukas, P. G., Escala, M. E. M., Ringbloom, K. G., Shih, D. J. H., Yang, J., Tegtmeyer, K., Park, J., Thomas, J. J., Selli, M. E., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15572-7 · Cited by 105
RAS-mutant leukaemia stem cells drive clinical resistance to venetoclax
Sango, J., Carcamo, S., Sirenko, M., Maiti, A., Mansour, H. M., Ulukaya, G. B., Tomalin, L. E., Cruz‐Rodriguez, N., Wang, T., Olszewska, M., et al. (2024) · Nature · doi:10.1038/s41586-024-08137-x · Cited by 107
Self-citationPaschka, P., Schlenk, R. F., Weber, D., Benner, A., Bullinger, L., Heuser, M., Gaidzik, V. I., Thol, F. R., Agrawal, M., Teleanu, V., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0129-6 · Cited by 107
Self-citationSommer, C., Cheng, H., Nguyen, D., Dettling, D. E., Yeung, Y. A., Sutton, J. E., Hamze, M., Valton, J., Smith, J. N. P., Djuretic, I. M., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.06.022 · Cited by 104
Current status and new treatment approaches in TP53 mutated AML
Hunter, A. M., & Sallman, D. A. (2019) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2019.05.004 · Cited by 102
Comprehensive diagnostics of acute myeloid leukemia by whole transcriptome RNA sequencing
Arindrarto, W., Borràs, D., de Groen, R. A. L., van den Berg, R. R., Locher, I. J., van Diessen, S. A. M. E., van der Holst, R., van der Meijden, E. D., Honders, M. W., de Leeuw, R. H., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0762-8 · Cited by 105
Zhong, Y., Qiu, R.-Z., Sun, S., Zhao, C., Fan, T.-Y., Chen, M., Li, N., & Shi, Z. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00696 · Cited by 103
Docking, R., Parker, J., Jädersten, M., Duns, G., Chang, L., Jiang, J., Pilsworth, J. A., Swanson, L., Chan, S. K., Chiu, R., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22625-y · Cited by 109
Sasaki, K., Kanagal‐Shamanna, R., Montalban‐Bravo, G., Assi, R., Jabbour, E., Ravandi, F., Kadia, T., Pierce, S., Takahashi, K., Nogueras Gonzalez, G., et al. (2020) · Cancer · doi:10.1002/cncr.32566 · Cited by 101
Inflammatory Signaling Pathways in Preleukemic and Leukemic Stem Cells
Hemmati, S., Haque, T. Z., & Gritsman, K. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00265 · Cited by 104
Iwai, K., Yaguchi, M., Nishimura, K., Yamamoto, Y., Tamura, T., Nakata, D., Dairiki, R., Kawakita, Y., Mizojiri, R., Ito, Y., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201708289 · Cited by 101
Genetic characterization of ABT-199 sensitivity in human AML
Bisaillon, R., Moison, C., Thiollier, C., Krošl, J., Bordeleau, M.-È., Lehnertz, B., Lavallée, V., MacRae, T., Mayotte, N., Labelle, C., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0485-x · Cited by 105
Molecular, clinical, and therapeutic determinants of outcome in NPM1 -mutated AML
Othman, J., Potter, N. E., Ivey, A., Tazi, Y., Papaemmanuil, E., Jovanovic, J. V., Freeman, S. D., Gilkes, A., Gale, R. E., Rapoz-D’Silva, T., et al. (2024) · Blood · doi:10.1182/blood.2024024310 · Cited by 101
Self-citationVenetoclax: A new wave in hematooncology
Mihályová, J., Jelı́nek, T., Growková, K., Hrdinka, M., Šimíček, M., & Hájek, R. (2018) · Experimental Hematology · doi:10.1016/j.exphem.2018.02.002 · Cited by 99
Yang, F., Long, N., Anekpuritanang, T., Bottomly, D., Savage, J. C., Lee, T. L., Solis-Ruiz, J. M., Borate, U., Wilmot, B., Tognon, C. E., et al. (2021) · Blood · doi:10.1182/blood.2021011354 · Cited by 102
Yan, F., Li, J., Milosevic, J., Petroni, R., Liu, S., Shi, Z., Yuan, S., Reynaga, J. M., Qi, Y., Rico, J., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1459 · Cited by 99
Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia
Lachowiez, C. A., Long, N., Saultz, J. N., Gandhi, A. P., Newell, L. F., Hayes‐Lattin, B., Maziarz, R. T., Leonard, J. T., Bottomly, D., McWeeney, S. K., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022009010 · Cited by 99
Baliakas, P., Tesi, B., Wartiovaara‐Kautto, U., Stray‐Pedersen, A., Friis, L. S., Dybedal, I., Hovland, R., Jahnukainen, K., Raaschou‐Jensen, K., Ljungman, P. T., et al. (2019) · HemaSphere · doi:10.1097/hs9.0000000000000321 · Cited by 98
Palangat, M., Anastasakis, D. G., Fei, D. L., Lindblad, K. E., Bradley, R. K., Hourigan, C. S., Hafner, M., & Larson, D. R. (2019) · Genes & Development · doi:10.1101/gad.319590.118 · Cited by 101
Kunimoto, H., Meydan, C., Nazir, A., Whitfield, J. T., SHANK, K. R., Rapaport, F., Maher, R., Pronier, E., Meyer, S. C., Garrett-Bakelman, F. E., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.11.012 · Cited by 102
Clinical implications of subclonal TP53 mutations in acute myeloid leukemia
Prochazka, K. T., Pregartner, G., Rücker, F. G., Heitzer, E., Pabst, G., Wölfler, A., Zebisch, A., Berghold, A., Döhner, K., & Sill, H. (2018) · Haematologica · doi:10.3324/haematol.2018.205013 · Cited by 99
Self-citationTherapeutic targeting of FLT3 and associated drug resistance in acute myeloid leukemia
Gebru, M. T., & Wang, H. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00992-1 · Cited by 98
The importance of FLT3 mutational analysis in acute myeloid leukemia
Patnaik, M. M. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1399312 · Cited by 98
IL1RAP potentiates multiple oncogenic signaling pathways in AML
Mitchell, K., Barreyro, L., Todorova, T. I., Taylor, S. J., Antony-Debré, I., Narayanagari, S.-R., Carvajal, L. A., Leite, J., Piperdi, Z., Pendurti, G., et al. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20180147 · Cited by 97
Beneyto-Calabuig, S., Merbach, A. K., Kniffka, J.-A., Antes, M., Szu-Tu, C., Rohde, C., Waclawiczek, A., Stelmach, P., Gräßle, S., Pervan, P., et al. (2023) · Cell Stem Cell · doi:10.1016/j.stem.2023.04.001 · Cited by 96
Eisfeld, A.-K., Mrózek, K., Kohlschmidt, J., Nicolet, D., Orwick, S. J., Walker, C. J., Kroll, K. W., Blachly, J. S., Carroll, A. J., Kolitz, J. E., et al. (2017) · Leukemia · doi:10.1038/leu.2017.86 · Cited by 96
Tóthová, Z., Krill-Burger, J. M., Popova, K. D., Landers, C. C., Sievers, Q. L., Yudovich, D., Belizaire, R., Aster, J. C., Morgan, E. A., Tsherniak, A., et al. (2017) · Cell stem cell · doi:10.1016/j.stem.2017.07.015 · Cited by 98
Kadia, T. M., Cortes, J. E., Ravandi, F., Jabbour, E. J., Konopleva, M. Y., Benton, C. B., Burger, J. A., Sasaki, K., Borthakur, G. M., Dinardo, C. D., et al. (2018) · The Lancet Haematology · doi:10.1016/s2352-3026(18)30132-7 · Cited by 96
Dickinson, M. J., Cherif, H., Fenaux, P., Mittelman, M., Verma, A. K., Portella, M. S. O., Burgess, P., Ramos, P. M., Choi, J., & Platzbecker, U. (2018) · Blood · doi:10.1182/blood-2018-06-855221 · Cited by 96
Gao, T., Ptashkin, R. N., Bolton, K. L., Sirenko, M., Fong, C., Spitzer, B. G., Menghrajani, K. N., Ossa, J. A., Zhou, Y., Bernard, E., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20565-7 · Cited by 100
Self-citationSmith, C. C., Levis, M. J., Perl, A. E., Hill, J. E., Rosales, M., & Bahceci, E. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021006489 · Cited by 99
Acute myeloid leukaemia genomics
Medinger, M., & Passweg, J. R. (2017) · British Journal of Haematology · doi:10.1111/bjh.14823 · Cited by 98
Eisfeld, A., Kohlschmidt, J., Mrózek, K., Blachly, J. S., Walker, C. J., Nicolet, D., Orwick, S. J., Maharry, S. E., Carroll, A. J., Stone, R. M., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0068-2 · Cited by 95
Nakamura, S., Yokoyama, K., Shimizu, E., Yusa, N., Kondoh, K., Ogawa, M., Takei, T., Kobayashi, A., Ito, M., Isobe, M., et al. (2019) · Blood · doi:10.1182/blood-2018-10-880690 · Cited by 95
Loss of KDM6A confers drug resistance in acute myeloid leukemia
Stief, S. M., Hanneforth, A.-L., Weser, S., Mattes, R., Carlet, M., Liu, W., Bartoschek, M. D., Moreno, H. D., Oettle, M., Kempf, J., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0497-6 · Cited by 99
Secondary leukemia in patients with germline transcription factor mutations (RUNX1, GATA2, CEBPA)
Brown, A. L., Hahn, C. N., & Scott, H. S. (2020) · Blood · doi:10.1182/blood.2019000937 · Cited by 97
Dovey, O. M., Cooper, J. L., Mupo, A., Grove, C. S., Lynn, C., Conte, N., Andrews, R., Pacharne, S., Tzelepis, K., Vijayabaskar, M. S., et al. (2017) · Blood · doi:10.1182/blood-2017-01-760595 · Cited by 94
New Insights from Studies of Clonal Hematopoiesis
Gibson, C. J., & Steensma, D. P. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3044 · Cited by 97
Zeidner, J. F., Vincent, B. G., Ivanova, A., Moore, D. T., McKinnon, K. P., Wilkinson, A. D., Mukhopadhyay, R., Mazziotta, F., Knaus, H. A., Foster, M. C., et al. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0070 · Cited by 94
The Bone Marrow Microenvironment Mechanisms in Acute Myeloid Leukemia
Pimenta, D. B., Varela, V. A., Datoguia, T. S., Caraciolo, V. B., Lopes, G. H., & Pereira, W. O. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.764698 · Cited by 100
Cystine uptake inhibition potentiates front-line therapies in acute myeloid leukemia
Pardieu, B., Pasanisi, J., Ling, F., Bello, R. D., Penneroux, J., Su, A. H., Joudinaud, R., Chat, L., Wu, H.-C., Duchmann, M., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01573-6 · Cited by 97
Circular RNAs of the nucleophosmin (NPM1) gene in acute myeloid leukemia
Lux, S., Blätte, T. J., Grasedieck, S., Cocciardi, S., ROUHI, A. M., Jongen‐Lavrencic, M., Paschka, P., Krönke, J., Gaidzik, V. I., Döhner, H., et al. (2017) · Haematologica · doi:10.3324/haematol.2017.172866 · Cited by 93
Self-citationYu, J., Li, Y., Li, T., Li, Y., Xing, H., Sun, H., Sun, L., Wan, D., Liu, Y., Xie, X., et al. (2020) · Experimental Hematology and Oncology · doi:10.1186/s40164-019-0158-5 · Cited by 95
Loo, S., Dillon, R. J., Ivey, A., Anstee, N. S., Othman, J., Tiong, I. S., Potter, N. E., Jovanovic, J. V., Runglall, M., Chong, C. C., et al. (2022) · Blood · doi:10.1182/blood.2022016567 · Cited by 93
Self-citationSabatier, M., Birsen, R., Lauture, L., Mouche, S., Angelino, P., Dehairs, J., Goupille, L., Boussaid, I., Heiblig, M., Boët, E., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0411 · Cited by 97
Metadata
- Authors
- Papaemmanuil, E., Gerstung, M., Bullinger, L., Gaidzik, V. I., Paschka, P., Roberts, N. D., Potter, N. E., Heuser, M., Thol, F., Bolli, N., Gundem, G., Van Loo, P., Martincorena, I., Ganly, P., Mudie, L., McLaren, S., O’Meara, S., Raine, K., Jones, D. R., Teague, J. W., Butler, A. P., Greaves, M. F., Ganser, A., Döhner, K., Schlenk, R. F., Döhner, H., & Campbell, P. J.
- Affiliations
- European Bioinformatics Institute (GB)
- Wellcome Sanger Institute (GB)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-06-09
- Volume
- 374
- Issue
- 23
- Pages
- 2209-2221
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4979995
- OpenAlex
- W2419140434
- Cited by
- 4,350
- References
- 40
- Citations by year
- 2026: 345 · 2025: 403 · 2024: 468 · 2023: 460 · 2022: 551 · 2021: 583 · 2020: 481 · 2019: 415 · 2018: 286 · 2017: 282 · 2016: 63
- FWCI
- 331.83
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- MDC Repository (Max-Delbrueck-Center for Molecular Medicine) (submittedVersion)
- Lirias (KU Leuven) (submittedVersion)
- Funders
- Wellcome Trust (103858/Z/14/Z, 105104, 077012/Z/05/Z, 077012, 103858, 105104/Z/14/Z, WT088340MA)
- Francis Crick Institute (10202)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- acute myeloid leukemia, driver mutations, genomic subgroups, prognostic stratification, TP53 mutation, aneuploidy, NPM1 mutation, IDH2 mutation, gene-gene interaction, co-mutation patterns, overall survival, intensive treatment
- MeSH terms
- DNA Methyltransferase 3A, Nucleophosmin, Adult, DNA (Cytosine-5-)-Methyltransferases, DNA Mutational Analysis, Epistasis, Genetic, Genotype, Humans, Middle Aged, Mutation, Nuclear Proteins, Prognosis, Prospective Studies, RNA Splicing, Leukemia, Myeloid, Acute, Proportional Hazards Models, Survival Analysis, Intracellular Signaling Peptides and Proteins, Gene Fusion
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
